A sponsor-focused guide to clinical trials in Bosnia and Herzegovina; covering EU accession momentum, ALMBIH oversight, Sarajevo and Banja Luka site capacity, ethnically diverse patient access, and regional trial strategy.
Bosnia and Herzegovina remains an underused but strategically relevant market for clinical trials in the western Balkans. Its EU accession trajectory, diverse population, low operating costs, and anchor sites in Sarajevo and Banja Luka make it a useful addition to regional study programmes.
Clinical trial regulation in Bosnia is complex due to the federal structure: both entities (Federation BiH and Republika Srpska) have separate regulatory and ethics committee systems. The Agency for Medicinal Products and Medical Devices of Bosnia and Herzegovina (ALMBIH) has national-level authority over medicines regulation, but clinical trial approvals involve parallel submissions to entity-level ethics committees as well. Researchers have identified establishment of a single national ethics committee and parallel submission processes as the two reforms most likely to improve Bosnia's trial capacity; both are likely to follow as part of EU accession harmonization.
The accession catalyst: Bosnia's EU candidate status and open accession negotiations are expected to drive regulatory simplification. The pattern in neighboring countries; Croatia (EU 2013), Bulgaria (EU 2007), Romania (EU 2007); shows that accession reliably transforms a fragmented national regulatory environment into a streamlined one. For sponsors building long-term Balkans relationships, Bosnia's pre-accession window is the right time to establish site connections.
Bosnia's 3.5 million people are divided among three constituent peoples; Bosniaks (~50%), Serbs (~31%), and Croats (~15%); with distinct genetic and cultural backgrounds. Sarajevo, the capital, is the most diverse city in the western Balkans and serves as Bosnia's primary medical research hub. Banja Luka, the administrative capital of Republika Srpska, hosts a secondary research cluster. The country's disease profile is dominated by cardiovascular disease and oncological conditions, creating large patient pools for Phase III commercial enrollment once the regulatory environment is sufficiently streamlined.
Bosnia's value lies in its EU accession trajectory, diverse patient populations, and very low operating costs; making it a natural add-on for sponsors already running Serbia, Croatia, or North Macedonia programmes.
EU candidate since Dec 2022; accession negotiations opened March 2024; regulatory harmonization expected to follow the accession pattern of Croatia, Bulgaria, and Romania; ALMBIH aligning with EU standards; ideal time to establish pre-accession relationships.
Very low trial operating costs; typically added to Serbia or Croatia programmes as a low-overhead addition; regional CROs (HungaroTrial, Clinres) operating with established site relationships; incremental 3.5M patient access in a diverse Bosniak-Serb-Croat population.
3.5M across three constituent peoples with distinct genetics; large treatment-naïve CVD and oncology populations; high patient motivation once enrolled; Sarajevo and Banja Luka as accessible urban catchments; historically low trial participation leaves large untapped potential.
University Clinical Centre Sarajevo; University Clinical Centre Banja Luka; University of Sarajevo medical school; GCP implemented in national law; HungaroTrial, Clinres Farmacija, and Oximio operating Bosnia sites; Balkan Clinical Research Registry established 2020.
Cardiovascular and oncology lead Bosnia's therapeutic mix, with neurology, psychiatry, endocrinology, and broader internal medicine areas providing additional opportunity.
Sarajevo anchors Bosnia's clinical research with KCUS at its centre; Banja Luka leads Republika Srpska. Mostar and Zenica extend regional reach into Hercegovina and Central Bosnia.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | University Clinical Centre of Sarajevo (KCUS) | Sarajevo | Bosnia's largest and most research-active hospital; University of Sarajevo Medical Faculty affiliate; oncology, cardiovascular, and neurology trials; Federation BiH research anchor; Phase II–IV commercial portfolio. |
| 02 | University Clinical Centre Banja Luka | Banja Luka | Republika Srpska research anchor; University of Banja Luka Medical Faculty affiliate; oncology, cardiovascular, and metabolic disease trials; access to RS population; Phase II–IV commercial portfolio. |
| 03 | Cantonal Hospital Zenica | Zenica | Central Bosnia regional hospital; oncology and cardiovascular trials; access to Central Bosnia patient population; Phase II–III commercial portfolio. |
| 04 | University Clinical Hospital Mostar | Mostar | Hercegovina region anchor; University of Mostar Medical Faculty affiliate; oncology, cardiovascular, and endocrinology trials; access to Hercegovina and border Croatia patient populations; Phase II–III portfolio. |
| 05 | Oncology Clinic; University Clinical Centre Sarajevo | Sarajevo | Bosnia's primary oncology research centre; Phase II–IV solid tumour and hematologic malignancy trials; University of Sarajevo affiliate; primary commercial oncology portfolio site (same location as KCUS). |
| 06 | General Hospital Prim. Dr. Abdulah Nakaš Sarajevo | Sarajevo | Major Sarajevo general hospital; cardiovascular, endocrinology, and internal medicine trials; access to Sarajevo metropolitan patient population; Phase II–III commercial portfolio; Federation BiH ethics committee registered. |
Bosnia's largest and most research-active hospital; University of Sarajevo Medical Faculty affiliate; oncology, cardiovascular, and neurology trials; Federation BiH research anchor; Phase II–IV commercial portfolio.
Republika Srpska research anchor; University of Banja Luka Medical Faculty affiliate; oncology, cardiovascular, and metabolic disease trials; access to RS population; Phase II–IV commercial portfolio.
Central Bosnia regional hospital; oncology and cardiovascular trials; access to Central Bosnia patient population; Phase II–III commercial portfolio.
Hercegovina region anchor; University of Mostar Medical Faculty affiliate; oncology, cardiovascular, and endocrinology trials; access to Hercegovina and border Croatia patient populations; Phase II–III portfolio.
Bosnia's primary oncology research centre; Phase II–IV solid tumour and hematologic malignancy trials; University of Sarajevo affiliate; primary commercial oncology portfolio site (same location as KCUS).
Major Sarajevo general hospital; cardiovascular, endocrinology, and internal medicine trials; access to Sarajevo metropolitan patient population; Phase II–III commercial portfolio; Federation BiH ethics committee registered.
These are the primary regulatory and industry bodies shaping Bosnia and Herzegovina's clinical research ecosystem.
National medicines regulatory authority; EU accession harmonization underway; dual-entity ethics committee system; Federation BiH and Republika Srpska separate ethics reviews required; legislative improvements expected as part of the EU accession process.
Regional CRO with Bosnia coverage; packages Bosnia into Balkans multi-country programmes; established site relationships; typically combined with Serbia, Croatia, and North Macedonia in regional Balkan submissions.
Regional clinical trial services; Bosnia and Herzegovina operations; regulatory and logistics support; established relationships with KCUS and University Clinical Centre Banja Luka.
For sponsors evaluating clinical trials in Bosnia and Herzegovina, the opportunity is defined by the country's regulatory pathway, investigator depth, patient access, and fit within a wider regional clinical research strategy. This profile is designed to support faster country feasibility, smarter site selection, and more informed clinical trial planning through Kitsa.
Bosnia and Herzegovina is the Balkans' most underdeveloped clinical research market; and its EU candidate status and open accession negotiations suggest that is beginning to change. The dual-entity regulatory structure is the primary operational challenge, but experienced regional CROs (HungaroTrial, Oximio, Clinres) have established pathways that make Bosnia viable as an add-on to Serbia, Croatia, or North Macedonia programmes. KCUS in Sarajevo and University Clinical Centre Banja Luka are credible commercial research sites. For sponsors with a long-term Balkans strategy, pre-accession relationship building in Bosnia follows the same logic that proved correct in Romania and Bulgaria a decade ago; and the 3.5 million treatment-naïve patients available once the regulatory environment simplifies represent genuine long-term value.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.